The inhibitory effects of the liver X receptor agonists on the EGFR associated signal pathway
LIU Siwen
FENG Jifeng
Abstract：Epidermal growth factor receptor tyrosine kinase inhibitor( EGFR?TKI) is the most widely used drug in the targeted treatment of lung cancer. However, almost all patients who are effective to this drug will eventually develop secondary resistance to EG?FR?TKI. The main mechanism of resistance is that the EGFR associated signal pathway was again activated. The liver X receptor( LXR) belongs to the family of nuclear receptor. Many studies showed the inhibitory effects of LXR agonists on the signal pathway of PI3K/AKT/NF?κB that are important to EGFR. Therefore, LXR agonists may be a potential new choice that can reverse the secondary resist?ance of EGFR?TKI. This paper summarizes the recent findings about the inhibitory effects of LXR agonists on PI3K/AKT/NF?κB path?way.
Keywords：Lung cancerEpidermal growth factor receptor tyrosine kinase inhibitor( EGFR-TKI)Drug resistanceLiver X receptor agonistReversing resistance
Publication Date：2015-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：5( 755-759 )